Log in

NASDAQ:ARDXArdelyx Stock Price, Forecast & News

$6.42
-0.18 (-2.73 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.42
Now: $6.42
$6.68
50-Day Range
$6.22
MA: $7.02
$7.86
52-Week Range
$2.10
Now: $6.42
$8.81
Volume423,100 shs
Average Volume899,200 shs
Market Capitalization$570.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Read More
Ardelyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.28 million
Book Value$2.10 per share

Profitability

Net Income$-94,940,000.00
Net Margins-1,403.90%

Miscellaneous

Employees88
Market Cap$570.93 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARDX stock has increased by 7.4% and is now trading at $6.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ardelyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.00. The biopharmaceutical company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $0.90 million. Ardelyx had a negative net margin of 1,403.90% and a negative return on equity of 77.23%. View Ardelyx's earnings history.

What price target have analysts set for ARDX?

5 brokerages have issued 1 year price objectives for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 86.9% from the stock's current price. View analysts' price targets for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Media headlines about ARDX stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ardelyx earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Ardelyx.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)
  • Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $6.42.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $570.93 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.